Antibody-Drug Conjugates-A Tutorial Review

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2021 Jun 2

PMID 34063364

Citations 75

Authors

Stephanie Baah

Mark Laws

Khondaker Miraz Rahman

Affiliations

Soon will be listed here.

Abstract

Antibody-drug conjugates (ADCs) are a family of targeted therapeutic agents for the treatment of cancer. ADC development is a rapidly expanding field of research, with over 80 ADCs currently in clinical development and eleven ADCs (nine containing small-molecule payloads and two with biological toxins) approved for use by the FDA. Compared to traditional small-molecule approaches, ADCs offer enhanced targeting of cancer cells along with reduced toxic side effects, making them an attractive prospect in the field of oncology. To this end, this tutorial review aims to serve as a reference material for ADCs and give readers a comprehensive understanding of ADCs; it explores and explains each ADC component (monoclonal antibody, linker moiety and cytotoxic payload) individually, highlights several EMA- and FDA-approved ADCs by way of case studies and offers a brief future perspective on the field of ADC research.

Citing Articles

Efficacy of Anti-Cancer Immune Responses Elicited Using Tumor-Targeted IL-2 Cytokine and Its Derivatives in Combined Preclinical Therapies.

Balkhi S, Bilato G, De Lerma Barbaro A, Orecchia P, Poggi A, Mortara L Vaccines (Basel). 2025; 13(1).

PMID: 39852848 PMC: 11768832. DOI: 10.3390/vaccines13010069.

FORCE platform overcomes barriers of oligonucleotide delivery to muscle and corrects myotonic dystrophy features in preclinical models.

Weeden T, Picariello T, Quinn B, Spring S, Shen P, Qiu Q Commun Med (Lond). 2025; 5(1):22.

PMID: 39827287 PMC: 11742727. DOI: 10.1038/s43856-025-00733-w.

Immunoconjugates as an Efficient Platform for Drug Delivery: A Resurgence of Natural Products in Targeted Antitumor Therapy.

Mihaylova R, Momekova D, Elincheva V, Momekov G Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770542 PMC: 11677665. DOI: 10.3390/ph17121701.

Addressing the unmet need in NSCLC progression with advances in second-line therapeutics.

Wang K, Leyba A, Hsu R Explor Target Antitumor Ther. 2025; 5(6):1297-1320.

PMID: 39759220 PMC: 11700623. DOI: 10.37349/etat.2024.00277.

Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms.

Jain A, Barge A, Parris C Oncogene. 2024; 44(4):193-207.

PMID: 39572842 PMC: 11746151. DOI: 10.1038/s41388-024-03227-6.

References

McCafferty J, Griffiths A, Winter G, Chiswell D . Phage antibodies: filamentous phage displaying antibody variable domains. Nature. 1990; 348(6301):552-4. DOI: 10.1038/348552a0. View

Gondi C, Rao J . Cathepsin B as a cancer target. Expert Opin Ther Targets. 2013; 17(3):281-91. PMC: 3587140. DOI: 10.1517/14728222.2013.740461. View

Lipman N, Jackson L, Trudel L, Weis-Garcia F . Monoclonal versus polyclonal antibodies: distinguishing characteristics, applications, and information resources. ILAR J. 2005; 46(3):258-68. DOI: 10.1093/ilar.46.3.258. View

Attarwala H . Role of antibodies in cancer targeting. J Nat Sci Biol Med. 2011; 1(1):53-6. PMC: 3217278. DOI: 10.4103/0976-9668.71675. View

Corcoran D, Lewis T, Nahar K, Jamshidi S, Fegan C, Pepper C . Effects of Systematic Shortening of Noncovalent C8 Side Chain on the Cytotoxicity and NF-κB Inhibitory Capacity of Pyrrolobenzodiazepines (PBDs). J Med Chem. 2019; 62(4):2127-2139. DOI: 10.1021/acs.jmedchem.8b01849. View

Bhattacharyya B, Wolff J . Maytansine binding to the vinblastine sites of tubulin. FEBS Lett. 1977; 75(1):159-62. DOI: 10.1016/0014-5793(77)80075-6. View

Harding F, Stickler M, Razo J, DuBridge R . The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs. 2010; 2(3):256-65. PMC: 2881252. DOI: 10.4161/mabs.2.3.11641. View

Goldmacher V, Kovtun Y . Antibody-drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells. Ther Deliv. 2012; 2(3):397-416. DOI: 10.4155/tde.10.98. View

Kovtun Y, Audette C, Ye Y, Xie H, Ruberti M, Phinney S . Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 2006; 66(6):3214-21. DOI: 10.1158/0008-5472.CAN-05-3973. View

10.

Kohler G, Milstein C . Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975; 256(5517):495-7. DOI: 10.1038/256495a0. View

11.

Dubowchik G, Firestone R, Padilla L, Willner D, Hofstead S, Mosure K . Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug Chem. 2002; 13(4):855-69. DOI: 10.1021/bc025536j. View

12.

Anami Y, Yamazaki C, Xiong W, Gui X, Zhang N, An Z . Glutamic acid-valine-citrulline linkers ensure stability and efficacy of antibody-drug conjugates in mice. Nat Commun. 2018; 9(1):2512. PMC: 6023893. DOI: 10.1038/s41467-018-04982-3. View

13.

Petersdorf S, Kopecky K, Slovak M, Willman C, Nevill T, Brandwein J . A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013; 121(24):4854-60. PMC: 3682338. DOI: 10.1182/blood-2013-01-466706. View

14.

Finbloom D, Abeles D, Rifai A, Plotz P . The specificity of uptake of model immune complexes and other protein aggregates by the murine reticuloendothelial system. J Immunol. 1980; 125(3):1060-5. View

15.

Selby C, Yacko L, Glode A . Gemtuzumab Ozogamicin: Back Again. J Adv Pract Oncol. 2019; 10(1):68-82. PMC: 6605703. View

16.

Bai R, Pettit G, Hamel E . Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol. 1990; 39(12):1941-9. DOI: 10.1016/0006-2952(90)90613-p. View

17.

Albanell J, Codony J, Rovira A, Mellado B, Gascon P . Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol. 2003; 532:253-68. DOI: 10.1007/978-1-4615-0081-0_21. View

18.

Pietersz G, Krauer K . Antibody-targeted drugs for the therapy of cancer. J Drug Target. 1994; 2(3):183-215. DOI: 10.3109/10611869408996804. View

19.

Polson A, Ho W, Ramakrishnan V . Investigational antibody-drug conjugates for hematological malignancies. Expert Opin Investig Drugs. 2010; 20(1):75-85. DOI: 10.1517/13543784.2011.539557. View

20.

Drachman J, Senter P . Antibody-drug conjugates: the chemistry behind empowering antibodies to fight cancer. Hematology Am Soc Hematol Educ Program. 2013; 2013:306-10. DOI: 10.1182/asheducation-2013.1.306. View